Home
History of Buteyko
How Does Buteyko Work?
Buteyko Courses
Research, Resources & Links
|
 |
 |
Buteyko Institute Method (BIM) Clinical Trials
International update
The Gisborne Trial - Dr Patrick McHugh, GP, Medical Director of Emergency Dept, Gisborne Hospital, New Zealand.
Presented at the 2nd International Buteyko Conference, Melbourne Australia, July 27, 2002.
Buteyko Breathing Techniques in Asthma.
Researchers: Fergus Aitcheson, Liz Buckley, Patrick McHugh, Bruce Duncan, Dennis Butcher.
Research Questions:
Is BIM effective in significantly reducing the need for beta 2 agonist use in asthmatics?
Is BIM effective in significantly reducing the need for inhaled steroid use in asthmatics?
Does instruction in BIM result in improved quality of life in asthmatics (as perceived by the patient)?
Does BIM result in improved or normalised lung function as measured by reduced minute volume ventilation rates, end tidal CO2 levels and FEV1/PEF?
Design: A prospective, blinded, randomised study comparing the effect of BIM
with asthma education in 40 subjects with asthma. The study was conducted from February to
October 2000.
Participants: Subjects recruited from the community (utilising General Practitioners) with asthma and significant medication use.
Main Outcome Measures:
Medication use
Forced expiratory volume in one second (FEV1)
End tidal CO2 levels
Resting minute volumes
Quality of life (QOL) score
With these measured at commencement, three months and six months.
Differences to Brisbane Study:
Participants followed for 6 months (compared to 3 months in Brisbane) post instruction.
Phone contacts following instruction matched.
Asthma education did allow educator preforming "control" education to use breathing exercises with some of these involving hypoventilation.
Results:
Mean reduction in Beta-agonist use
| BIM | Control | |
| At 6 weeks | 94% | 56% | p=0.001 |
| 3 months | 86% | 51% | p=0.007 |
| 6 months | 85% | 37% | p=0.102 |
Mean reduction in inhaled steroid use
| BIM | Control | |
| At 6 weeks | 34% | -10% | p=0.032 |
| 3 months | 36% | -2% | p=0.011 |
| 6 months | 50% | -1% | p=0.003 |
No significant improvement in quality of life among those assigned to the BBT compared with the control group was discerned using the AQLQ.
No significant differences were sustained over 6 months in PEF/FEV1, end tidal CO2 or minute volumes between treatment and control group.
Back to Research, Resources & Links.
back to top
|
Test Your Breathing
Who Can Buteyko Help?
Client Testimonials
FAQs
Buteyko Institute
|